1 min read
Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years
The Phase 2 open-label extension showed a 38% improvement in clinical benefit with a 60 mg regimen given twice yearly.

Biogen released two-year Phase 2 extension findings Tuesday for diranersen in early Alzheimer’s disease, describing slower clinical decline and a 38% improvement in clinical benefit with 60 mg given twice a year.
The results came from an open-label extension of a Phase 2 study.